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Background/Aims: The application of glycated hemoglobin (HbA1c) for the diagnosis of diabetes is currently under 
extensive discussion. In this study, we explored the validity of using HbA1c as a screening and diagnostic test in Chinese 
subjects recruited in Nanjing, China. 
Methods: In total, 497 subjects (361 men and 136 women) with fasting plasma glucose (PG) ≥ 5.6 mmol/L were recruited 
to undergo the oral glucose tolerance test (OGTT) and HbA1c test. Plasma lipid, uric acid, and blood pressure were also 
measured. 
Results: Using a receiver operating characteristic curve, the optimal cutoff point of HbA1c related to diabetes diagnosed 
by the OGTT was 6.3%, with a sensitivity and specificity of 79.6% and 82.2%, respectively, and the area under the curve 
was 0.87 (95% confidence interval, 0.83 to 0.92). A HbA1c level of 6.5% had a sensitivity and specificity of 62.7% and 
93.5%, respectively. When comparing the HbA1c ≥ 6.5% or OGTT methods for diagnosing diabetes, the former group had 
significantly higher HbA1c levels and lower levels of fasting and 2-hour PG than the latter group. No significant difference 
was observed in the other metabolism indexes between the two groups.  
Conclusions: Our results suggest that HbA1c ≥ 6.5% has reasonably good specificity for diagnosing diabetes in Chinese 
subjects, which is in concordance with the American Diabetes Association recommendations. 
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IntRoduCtIon
The oral glucose tolerance test (OGTT) is regarded as 
the “gold standard” for the diagnosis of diabetes mellitus 
(DM) and impaired glucose regulation (IGR) [1]. However, 
the OGTT is poorly reproducible, time-consuming, and 
unsuitable for large-scale screening [2]. Clinical doctors 
have begun to recognize that point-of-care blood glucose 
testing cannot accurately monitor glycemic fluctuation, 
or “drift of glucose,” and its clinical significance. Glycated 
hemoglobin (HbA1c) is an indicator that reflects the 
average plasma glucose (PG) levels over the recent 2 to 
3 months. The HbA1c test is relatively stable and has less 
variability and fewer interferences with environmental 
factors than point-of-care glucose testing [3,4]. 
Recently, the application of HbA1c in the diagnosis 
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of DM was fully endorsed by The American Diabetes 
Association (ADA) in an updated and promulgated 2010 
version of “The Clinical Practice Recommendations 
for the Diagnosis and Treatment of Diabetes” [5]. The 
recommendation was made that HbA1c ≥ 6.5% can be used 
as a diagnostic criteria for DM. In this study, we examined 
the HbA1c and OGTT results of 497 Chinese subjects with 
impaired fasting glucose (IFG). We evaluated the validity 
of using HbA1c as a screening and diagnostic test for 
diabetes in Chinese patients with IFG. 
Methods
subjects
The health care center of Jiangsu Province Institute of 
Geriatrics has provided diabetes-screening services to 
the community of Nanjing City since 2009. In the period 
between September 2009 and February 2010, 3,012 
subjects without a past history of chronic illness attended 
the center and received a fasting PG test. Among them, 
497 (16.5%) subjects (361 men and 136 women) had fasting 
PG levels ≥ 5.6 mmol/L. Their mean (± SD) age was 62.2 
± 11.3 years. All subjects had not received prior OGTT 
assessment or had a past history of DM or IGR and had 
not received lifestyle or pharmacological intervention, 
such as dietary counseling, exercise, or antidiabetic drugs. 
Patients with anemia were excluded early from the study, 
although detailed hemoglobinopathy screening was not 
performed. The Jiangsu Province Health Administrative 
Department and its Ethics Committee approved the study. 
All subjects consented to participate in the study.
Assessment
After overnight fasting, each subject was evaluated 
using simple health assessments and was administered a 
75-g OGTT (10-12 hours). The health assessments included 
measurement of blood pressure (BP), body weight, height, 
and waist circumference (WC). BP was measured twice 
using a standard mercury manometer in the sitting 
position after the subject rested for at least 15 minutes. 
The average of the two measurements was recorded. Body 
weight, height, and WC were measured with the patient 
wearing light clothing and no shoes. The minimum waist 
measurement between the xiphisternum and umbilicus 
was taken as the WC. Body mass index (BMI) was 
calculated as the weight (kg) divided by the height squared 
(m
2). 
Prior to the OGTT, all subjects had at least 3 days of 
unrestricted diet (> 150 g of carbohydrate daily). HbA1c, 
lipid profiles (total cholesterol [TC], triglyceride [TG], 
high-density lipoprotein cholesterol [HDL-C]) and uric 
acid (UA) were measured in the fasting blood samples. All 
blood specimens were analyzed at the Central Laboratory 
of Endocrinology and Metabolism, Jiangsu Province 
Institute of Geriatrics. PG was assayed using the glucose 
oxidase method. The HbA1c assay was standardized 
under the National Glycohemoglobin Standardization 
Program with traceability to the Diabetes Control 
and Complications Trial (DCCT) reference method. 
The test used ion exchange high-performance liquid 
chromatography (HLC-723G7) with an inter-assay 
coefficient of variation (CV) at 0.2% and an intra-assay CV 
at 2.0%. The lipid profiles and UA were measured by the 
automatic biochemistry analyzer (Hitachi 7000, Hitachi 
Ltd., Tokyo, Japan). Low-density lipoprotein cholesterol 
was calculated using Friedewald’s equation [6].
Glycemic status was classified according to the ADA 
2010 diagnostic criteria using PG values in the OGTT [1]. 
The definition of normal glucose tolerance (NGT) was 
modified in this group of subjects with IFG and defined as 
fasting PG ≥ 5.6 and < 7.0 mmol/L and 2-hour PG < 7.8 
mmol/L. IGR was defined as fasting PG ≥ 5.6 and < 7.0 
mmol/L and 2-hour PG ≥ 7.8 and < 11.1 mmol/L. DM was 
defined as fasting PG ≥ 7.0 and/or 2-hour PG ≥ 11.1 mmol/
L. Test results were further validated using HbA1c ≥ 6.5%.
statistical analysis
Statistical analysis was performed using the software 
SAS version 15.0 (SAS Inc., Cary, NC, USA). Continuous 
variables were presented as the mean ± SD and categorical 
data as number (%). Group data were compared by normal 
testing and the test for homogeneity of variance. The 
difference in the mean between groups was analyzed using 
one-way analysis of variance (ANOVA) and the intergroup 
comparison was made using the least significant difference 
(LSD) test. A p value < 0.05 (two-tailed) was considered 
statistically significant. The optimal cutoff point of HbA1c 
in the patients with DM diagnosed with the OGTT was 
calculated by utilizing the receiver operating characteristic 
(ROC) curve. yu y, et al. A1c in diagnosing Dm in Chinese    43
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Results
Of the 497 subjects, according to the OGTT results, 
155 (31.2%) subjects had DM, 230 (46.3%) had IGR, and 
112 (22.5%) had NGT. Table 1 summarizes the clinical 
parameters of these subjects according to their glycemic 
status. In particular, HbA1c values in subjects with NGT, 
IGR, and DM were 5.84 ± 0.77%, 6.06 ± 0.77%, and 6.88 
± 0.99%, respectively (p value < 0.05 comparing the three 
groups). Age, BMI, WC, systolic BP, fasting and 2 hours 
PG, TG, and HDL-C were significantly different between 
any two groups of NGT, IGR, and DM.
In total, 213 subjects with DM were diagnosed by either 
HbA1c ≥ 6.5% and/or the OGTT. Among these 213 subjects, 
154 were diagnosed by HbA1c and 155 were diagnosed by 
the OGTT; 96 fulfilled both criteria (the “overlapping” 
group), accounting for 45.1% of all the newly diagnosed 
patients who had DM. Table 2 summarizes the clinical 
characteristics of the DM group diagnosed by the different 
criteria with or without excluding the “overlapping” 
group. In those diagnosed by HbA1c, the HbA1c level was 
higher, and the fasting and 2-hour PG values were lower 
than those diagnosed by the OGTT. After excluding the 
“overlapping” group, the DM subjects, regardless of the 
diagnostic test used, had significantly lower fasting and 
2-hour PG and HbA1c levels, compared with those included 
in the “overlapping” group. No significant difference was 
noted for other clinical indexes such as BP and lipid profile 
(Table 2). 
With OGTT as the reference standard for diagnosing 
DM, the optimal cutoff point of HbA1c was 6.3%, with 
sensitivity and specificity at 79.6% and 82.2%, respectively. 
The corresponding area under the curve (AUC) of the ROC 
curve was 0.87 (95% confidence interval [CI], 0.83 to 0.92). 
Using HbA1c ≥ 6.5% as a diagnostic tool, the sensitivity 
and specificity were 62.7% and 93.5%, respectively (Fig. 1).
dIsCussIon
DM is an important clinical and social health problem. 
Alarmingly, many undiagnosed subjects remain, who 
may account for up to 50% of the diabetic population [7]. 
The onset time of type 2 diabetes has been estimated to 
be 9 to 12 years before diagnosis. Currently, the OGTT 
table 1. Clinical parameters of 497 Chinese subjects according to their glycemic status based on oGtt results
Total (n = 497) NGT (n = 112) IGR (n = 230) DM (n = 155)
Age, yr   62.2 ± 11.3   60.3 ± 10.8
a    62.3 ± 11.5
b    63.9 ± 11.0
c
men, n (%) 361 (72.6) 78 (69.6) 164 (71.3) 119 (76.8)
BMI, kg/m
2 25.0 ± 3.3 24.1 ± 2.8
a   25.1 ± 3.8
b 25.7 ± 2.8
c
WC (men), cm  89.7 ± 7.8 86.8 ± 7.4
a  90.5 ± 7.4
b 90.5 ± 8.3
c
WC (women), cm   83.8 ± 10.7 78.2 ± 7.8
a    84.5 ± 11.0
b    88.3 ± 10.7
c
systolic BP, mmHg 126 ± 15 123 ± 15
a    124 ± 13
b 129 ± 16
c
Diastolic BP, mmHg 80 ± 9 79 ± 9 79 ± 9  80 ± 9
Fasting PG, mmol/L   6.4 ± 1.0   5.6 ± 0.4
a    6.2 ± 0.5
b   7.6 ± 4.4
c
2-hr PG, mmol/L   9.3 ± 3.4   6.4 ± 0.9
a    8.3 ± 1.6
b 13.0 ± 3.3
c
HbA1c, %   6.3 ± 0.8   5.8 ± 0.8
a     6.1 ± 0.8
b   6.9 ± 1.0
c
TC, mmol/L   5.0 ± 0.9 4.9 ± 1.0  5.10 ± 0.8 5.1 ± 1.0
TG, mmol/L   1.8 ± 1.0   1.5 ± 0.9
a    1.9 ± 1.1
b   1.9 ± 1.0
c
HDL-C, mmol/L   1.3 ± 0.3   1.3 ± 0.4
a     1.3 ± 0.3
b   1.2 ± 0.3
c
LDL-L, mmol/L    3.1 ± 0.8   3.0 ± 0.9   3.1 ± 0.7  3.1 ± 0.9
UA, µmol/L  390 ± 111 379 ± 111   398 ± 103 388 ± 110
Values are presented as mean ± SD.
OGTT, oral glucose tolerance test; NGT, normal glucose tolerance; IGR, impaired glucose regulation; Dm, diabetes mellitus; BmI, body 
mass index; WC, waist circumference; BP, blood pressure; PG, plasma glucose; HbA1c, glycated hemoglobin; TC, total cholesterol; TG, 
triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; UA, uric acid.
a, b, cp value < 0.05 for comparison between NGT and IGR, IGR and DM, and DM and NGT, respectively, based on the least significant 
difference test.44    The Korean Journal of Internal Medicine Vol. 27, No. 1, march 2012
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is still the “gold standard” for diagnosing DM and IGR. 
However, the glucose values obtained by the OGTT are 
poorly reproducible, and many problems related to the 
standardization of glucose testing remain [2,8,9]. In 
addition, the subjects need to receive strict preparation 
before the OGTT. Due to the above reasons, an increasing 
demand for adopting HbA1c to diagnose DM has arisen. 
Recently, the ADA revised their “Clinical Practice 
Recommendations for the Diagnosis and Treatment 
of Diabetes” such that HbA1c was recommended for 
diagnosing diabetes [1]. The International Diabetes 
Federation, the European Association for the Study 
of Diabetes, and the World Health Organization have 
also incorporated HbA1c as an alternative method for 
diagnosing DM [10]. 
Our results showed that the comparison of HbA1c 
levels between any two groups of NGT, IGR, and DM had 
significant differences (p value < 0.01). This observation 
might be explained by recent evidence showing that HbA1c 
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Figure 1. The ROC curve for diabetes diagnosis using HbA1c, 
with OGTT as the reference standard. ROC, receiver operating 
characteristic; HbA1c, glycated hemoglobin; OGTT, oral glucose 
tolerance test; AUC, area under the curve; CI, confidence interval. 
table 2. Comparison of clinical parameters among 213 subjects with diabetes diagnosed by different methods
Diabetes diagnosis
Including ‘overlapping’ group
a separating ‘overlapping’ group
a
By HbA1c
(n = 154)
By OGTT
(n = 155)
By HbA1c only
(n = 58)
By OGTT only
(n = 59)
‘Overlapping’ group
(n = 96)
Age, yr   64.6 ± 10.5  63.0 ± 11.3 65.5 ± 10.4   64.4 ± 12.4   63.6 ± 11.0
men, n (%) 103 (66.9) 119 (76.8) 36 (62.1) 52 (88.1) 69 (71.9)
BMI, kg/m
2   25.5 ± 2.9 25.7 ± 2.7 24.8 ± 2.8 25.5 ± 2.5 25.8 ± 2.9
WC, cm (men) 92.3 ± 8.1 91.1 ± 8.5 92.1 ± 7.1 89.5 ± 8.0 92.1 ± 8.6
WC, cm (women)  82.1 ± 8.5 84.7 ± 8.4 83.2 ± 8.4 85.6 ± 6.6 83.7 ± 8.3
systolic BP, mmHg   127 ± 12 128 ± 18 125 ± 12 130 ± 17 129 ± 12
Diastolic BP, mmHg 80 ± 8  80 ± 10 79 ± 8   80 ± 10 80 ± 8
Fasting PG, mmol/L   6.9 ± 1.2   7.2 ± 1.1
b     6.1 ± 0.8
c       6.9 ± 0.9
b,c    7.4 ± 1.2
2-hr PG, mmol/L  11.7 ± 3.8  13.0 ± 3.2
b     8.4 ± 2.2
c     12.0 ± 3.0
b,c  13.7 ± 3.3
HbA1c, %    7.1 ± 0.8    6.9 ± 1.0
b    6.8 ± 0.8
c        6.5 ± 0.9
b,c    7.3 ± 0.9
TC, mmol/L     5.0 ± 0.9   5.1 ± 0.9   4.9 ± 0.8   5.0 ± 1.0    5.1 ± 0.9
TG, mmol/L     2.0 ± 1.3    1.9 ± 1.3   1.9 ± 1.1   1.8 ± 1.2     1.9 ± 0.9
HDL-C, mmol/L     1.3 ± 0. 5  1.3 ± 0.5   1.3 ± 0.3   1.2 ± 0.3     1.3 ± 0.6
LDL-L, mmol/L    3.2 ± 0.8  3.2 ± 0.8    3.1 ± 0.6   3.0 ± 0.8   3.2 ± 0.8
UA, µmol/L     390 ± 114  391 ± 109   403 ± 130   410 ± 119   377 ± 101
Values are presented as mean ± SD.
HbA1c, glycated hemoglobin; OGTT, oral glucose tolerance test; BMI, body mass index; WC, waist circumference; BP, blood pressure; 
PG, plasma glucose; TC, total cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein 
cholesterol; UA, uric acid.
a‘Overlapping’ group = diabetes diagnosed by both HbA1c and OGTT.
bp value < 0.05 between HbA1c and OGTT groups before or after removing the ‘overlapping’ group.
cp value < 0.05 between HbA1c and ‘overlapping’ groups, or OGTT and ‘overlapping’ groups.yu y, et al. A1c in diagnosing Dm in Chinese    45
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could reflect different stages of glucose metabolism [11]. 
Compared to PG as a point-of-care test, HbA1c reflects 
the patients’ average glycemic status over the past 2 to 
3 months and it is not influenced by current diet, drug 
treatment, and blood sampling time [12-14]. However, 
many studies have found that ethnicity might influence 
the level of HbA1c [14-16]. A large international study 
comparing the relationship between HbA1c and the average 
PG levels among African Americans and Caucasians 
showed that African Americans had a higher HbA1c under 
the same PG level [14].
In our study, the optimal cutoff point for HbA1c in 
diagnosing DM was 6.3% with a sensitivity and specificity 
of 79.6% and 82.2%, respectively. In addition, the AUC 
under the ROC curve was high at 0.87 (95% CI, 0.83 to 
0.92). These values are similar to the reported optimal 
HbA1c cutoff point of 6.2% used by the United Kingdom 
Prospective Diabetes Study (UKPDS), 6.1% by the DCCT 
[17], 6.1% by Hu et al. [18] from Shanghai, China, and 6.1% 
by Mohan et al. [19] in Asian Indians, but higher than that 
reported by Nakagami et al. [20] from the Japan National 
Diabetes Survey (5.6%). Our study had 259 subjects whose 
HbA1c levels were lower than 6.3%. In other words, if 
only those with HbA1c ≥ 6.3% need to receive an OGTT to 
confirm their glycemic status, then 52.2% (259/497) of the 
subjects would not require an OGTT. Currently, the ADA 
recommends that either HbA1c (≥ 6.5%) or the OGTT can 
be used as diagnostic criteria for DM. Since HbA1c may 
be affected by ethnicity, understanding the effectiveness 
of using HbA1c to diagnose DM in the Chinese population 
is important. Based on the ROC curve, the sensitivity 
and specificity were 62.7% and 93.5%, respectively, when 
using HbA1c ≥ 6.5% to diagnose DM in our population. 
Similarly, various studies reported that using HbA1c ≥ 6.5% 
for diagnosis gave a high specificity (> 95%), while the 
sensitivity was suboptimal (40-50%) [21,22]. Nevertheless, 
since DM is a serious disease with significant medical 
implications, a more specific diagnostic approach is 
necessary to avoid a large number of false positives. 
In this study, we enrolled subjects with fasting PG ≥ 5.6 
mmol/L (those with IFG) so as to recruit more patients 
with IGR or DM. Therefore, the HbA1c levels of the 
subjects may be slightly higher than those of the general 
community. Among the 497 subjects in our study, 42.9% 
(n = 213) were diagnosed with diabetes by HbA1c (n = 154), 
the OGTT (n = 155), or both (n = 96). This particularly 
high prevalence of diabetes should not be interpreted 
as the usual rate in the general population in Jiangsu 
Province. We found that the PG and HbA1c levels were 
not well correlated in our population, especially among 
the subjects with DM who were diagnosed by either one 
but not both criteria. The HbA1c level was higher, while 
the fasting and 2-hour PG was lower in subjects with DM 
diagnosed by HbA1c as compared to those diagnosed by the 
OGTT. This result highlights the importance of validating 
the recommended HbA1c diagnostic level in different 
populations before formally adopting it. The International 
Expert Committee recommended HbA1c ≥ 6.5% as 
the diagnostic cutoff for DM based on the existence of 
retinopathy with data from the Evaluation of Screening 
and Early Detection Strategies for Type 2 Diabetes and 
Impaired Glucose Tolerance (DETECT-2) Study [10,23]. 
Our data examined this approach and reported a high 
specificity of 93.5% with a HbA1c cutoff level of 6.5%, 
suggesting this newly recommended diagnostic tool could 
be applicable to the Chinese population, thus validating 
the recommended standards of the ADA [1]. However, our 
sample size was relatively small and with a low proportion 
of women (27.4%). Further studies are needed to confirm 
our results.   
In conclusion, with OGTT as the “gold standard” 
reference for diagnosing DM in Chinese in Nanjing, the 
optimal cutoff point of HbA1c was 6.3% with a sensitivity 
and specificity of 79.6% and 82.2%, respectively. HbA1c 
≥ 6.5% has reasonably good specificity (93.5%) for 
diagnosing diabetes, which is in concordance with the 
ADA recommendations. 
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